It is possible that some patients with HER2-positive breast cancer will have a significant response to trastuzumab, and one option may be to consider de-escalation therapy without chemotherapy, for example, in elderly patients who wish to avoid side effects as much as possible. Here, ERBB2 is linked to breast cancer.